CD19 and neoplasm: These include targets expressed in hematological malignancies (such as BCMA, CD19, CD20, CD13, CD38, CD33, CD72, and CD7), solid tumors (such as PSMA, FGFR4, and GPC2) and tumor microenvironment (such as VEGFR2, EIIIB, PD-L1, and CD105) [69, 71, 75–83].